The rapid emergence of multidrug-resistant (MDR) bacteria highlights the urgent need for antibacterial agents that operate through previously unexplored mechanisms. PlsY, a seven-transmembrane glycerol-3-phosphate acyltransferase that catalyzes an essential step in bacterial phospholipid biosynthesis, represents an attractive antibacterial target. However, inhibitor development has so far focused on substrate analogues. Here, we identify Gpatin, a small-molecule inhibitor of PlsY, through structure-based virtual screening and biochemical characterization. Gpatin inhibits PlsY enzymes from multiple pathogenic bacteria and displays antibacterial activity across clinically relevant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae . Cryo-electron microscopy reveals that Gpatin binds within a partially membrane-exposed pocket formed by the C-terminal transmembrane bundle and surrounding phospholipids, overlapping the substrate-binding site and explaining its competitive inhibitory activity. Moreover, Gpatin binding induces a large-scale rearrangement of the transmembrane architecture that disrupts formation of the catalytic phosphate hole required for catalysis, thereby stabilizing PlsY in an inactive conformation. In murine infection models, Gpatin exhibits in vivo antibacterial activity against S. aureus and S. pneumoniae . Together, our findings further establish PlsY as a chemically tractable antibacterial target and reveal an unexpected conformational vulnerability that can be exploited for inhibitor development.